• New international advisory board members: MrGlenn Cross (Australia), Dr Jittaporn Wattanaseree (Thailand) and Ms Carol Aebi(Switzerland)
• Management team appointment: Mr PierreNathie of Med2Mark as VP, Commercialisation

ZURICH, SWITZERLAND - EQS Newswire - 13 October 2020 - Achiko AG (SWX:ACHI, ISIN CH0522213468) is pleasedto announce an update to its management and advisory team.

As progress continues towards the launch of Achiko's Covid-19 test kit ledby a world-class research and development team, the Company has establishedan advisory board of international experts in the medtech, biotech andinnovation fields and appointed a head of commercialisation, effectiveimmediately, as it prepares for global expansion.

Advisory Board

- Mr Glenn Cross is Director at leading tech andhealthcare companies Horizon 3 Biotech, Captix Biomedical, and Grey Innovation.He will join Achiko's Board of Directors later this year.

- Dr Jittaporn Wattanaseree is a lecturer andtrainer experienced in the pharmaceutical and biopharmaceutical fields over allstages of drug development from research through commercialisation.

- Ms Carol Aebi is a Strategist and the Head ofBusiness Analysis at Swiss software engineering firm AdNovum.

Management Appointment

- Mr Pierre Nathie joins Achiko's existing management teamas the Vice President, Commercialisation. Currently the Managing Director ofMed2Mark, an international consulting firm specialising in thecommercialisation of health-tech innovations, Pierre brings to Achiko 25+years' experience in launching of innovative medtech and biotech products andsolutions in international markets.

"We're excited about the progress with Gumnuts, working withRegenacellx.sL, the novel covid testing technology. We recognise that to makethis a success, the company needs to broaden its expertise and executioncapability and we're excited to be joined by Glenn, Dr Jittaporn, Carol andPierre," said Steven Goh, Achiko CEO.

"We've started clinical evaluation trials and we're updating ourregulatory strategy to broaden our footprint. Unlike the more popular PCR andAntigen approaches, our differentiated approach has a supply chain that offersan alternative to resolving capacity issues with testing, as well as a likelyfriendly patient experience and a cost profile that other testing approacheshave yet to meet."

"Strengthening our board and management team, is about getting tomarket with the right level of care and diligence, and in a timelymanner."

About Achiko AG

Headquartered in Switzerland, with a global market focus, Achiko AG(SWX:ACHI, ISIN CH0522213468) is an entrepreneurial platform company, utilisingthe knowledge and experience of its people and key technologies to enabletransformation in various industries.

Through innovations in technology and regulation along with the company'sunique operating footprint from Europe to Asia, Achiko seeks to transformmarkets and bring unique value to its customers, people, and shareholders.Achiko's core platform consists of user registration and payment services whichare accessible to application developers. A messaging service and othercommunity based social features are being launched in late 2020. Achikosupports innovations in healthcare through its Teman Sehat ("HealthBuddy") ecosystem, a novel testing technology being developed withRegenacellx.sl, as well as consumer payments and finance and games andentertainment.

For any inquiries regarding Gumnuts or Teman Sehat, please contact info@achiko.com

Further information about Achiko can be found at https://www.achiko.com

Further information about the Teman Sehat ecosystem can be found at https://www.temansehat.co

Further information about Regenacellex.sl can be found at https://regenacellx.com

Disclaimer
This communication expressly or implicitly contains certain forward-lookingstatements concerning Achiko AG and its business. Such statements involvecertain known and unknown risks, uncertainties and other factors, which couldcause the actual results, financial condition, performance or achievements ofAchiko AG to be materially different from any future results, performance orachievements expressed or implied by such forward-looking statements. Achiko AGis providing this communication as of this date and does not undertake toupdate any forward-looking statements contained herein as a result of newinformation, future events or otherwise.